Enanta Pharmaceuticals Will Provide An Update Across Its Pipeline And Plans For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference On Wednesday, January 10, 2024

1/4/24 7:07:18 AM ET

$ENTA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ENTA alert in real time by email

Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024
Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season
Anticipate Challenge Study Data for EDP-323, an L-Protein Inhibitor in Development to Treat RSV, in 3Q 2024

Get the next $ENTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENTA

Date	Price Target	Rating	Analyst
8/9/2023	$14.00	Neutral → Underweight	JP Morgan
8/8/2023	$49.00 → $18.00	Buy → Hold	Jefferies
12/9/2022	$56.00	Buy	H.C. Wainwright
7/6/2022	$62.00	In-line → Outperform	Evercore ISI
6/1/2022	$39.00	Underperform → In-line	Evercore ISI
2/9/2022	$80.00 → $68.00	Market Perform	SVB Leerink
1/13/2022	$85.00 → $80.00	Market Perform	SVB Leerink
11/24/2021	$55.00 → $73.00	Perform	Oppenheimer

More analyst ratings

$ENTA
Press Releases

Fastest customizable press release news feed in the world

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and
9/26/24 6:00:00 AM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September: Baird 2024 Global Healthcare Conference: Fireside Chat at 2:35 p.m. ET on September 10, 2024 H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat at 10:00 a.m. ET on September 11, 2024 2024 Cantor Global Healthcare Conference: Fireside Chat at 10:55 a.m. ET on September 17, 2024 A live webcast of each event will be accessible by visiting the "Events and Presentations" section on t
9/3/24 7:00:00 AM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are
8/5/24 4:01:00 PM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac
4/30/24 7:00:00 AM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi
8/8/22 4:00:00 PM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys
1/26/21 7:00:00 AM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and
9/26/24 6:00:00 AM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are
8/5/24 4:01:00 PM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are commit
5/6/24 4:01:00 PM ET
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care

Enanta Pharmaceuticals Will Provide An Update Across Its Pipeline And Plans For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference On Wednesday, January 10, 2024

Chat with this insight

Recent Analyst Ratings for $ENTA

$ENTA SEC Filings

SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by Enanta Pharmaceuticals Inc.

$ENTA Market Insights

Live Market Insights

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $27

JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $22

Enanta Pharma Q2 2024 GAAP EPS $(1.47) Misses $(1.33) Estimate, Sales $17.054M Beat $16.522M Estimate

$ENTA Press Releases

Fastest customizable press release news feed in the world

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

$ENTA Leadership Updates

Live Leadership Updates

$ENTA Financials

Live finance-specific insights

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

$ENTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

$ENTA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

Enanta Pharmaceuticals downgraded by Jefferies with a new price target

H.C. Wainwright initiated coverage on Enanta Pharmaceuticals with a new price target

$ENTA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 2,933 shares, decreasing direct ownership by 30% to 18,784 units (SEC Form 4)

Chief Medical Officer Rottinghaus Scott T. sold $190,747 worth of shares (11,945 units at $15.97) and exercised 5,375 shares at a strike of $8.99, decreasing direct ownership by 23% to 21,717 units (SEC Form 4)

Chief Product Strategy Officer Kieffer Tara Lynn sold $89,590 worth of shares (7,266 units at $12.33), decreasing direct ownership by 18% to 32,341 units (SEC Form 4)

Recent Analyst Ratings for
$ENTA

$ENTA
SEC Filings

$ENTA
Market Insights

$ENTA
Press Releases

$ENTA
Leadership Updates

$ENTA
Financials

$ENTA
Large Ownership Changes

$ENTA
Analyst Ratings

$ENTA
Insider Trading